Month: August 2022

– Revenue for Second Quarter of Fiscal 2023 Increased 31.5% to $496.5 million – – Record Quarterly EPS of $1.10 for Second Quarter of Fiscal 2023 – – Increases Fiscal 2023 Modeling Assumptions, Expects Fiscal 2023 EPS in Range of $3.70-$4.00 – WEST FARGO, N.D., Aug. 25, 2022 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, today reported financial results for the fiscal second quarter ended July 31, 2022. David Meyer, Titan Machinery’s Chairman and Chief Executive Officer, stated, “We are pleased to deliver second quarter earnings per share of $1.10 — which marks the highest quarterly earnings performance in our Company’s history. This is the result of our team’s unrelenting focus on customer...

ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective Negative Allosteric Modulator of the 7 nicotinic acetylcholine receptor (“7 receptor”) for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). During the fiscal year ended 30 June 2022, Bionomics made several advancements with the ongoing clinical development of BNC210. After receiving US...

Neurostimulation devices industry is projected to register 11% CAGR between 2022 and 2030 owing to rising acceptance of minimally invasive surgeries across the globe. Selbyville, Delaware, Aug. 25, 2022 (GLOBE NEWSWIRE) — Neurostimulation Devices Market value is set to cross USD 20.1 billion by 2030, according to a new research report by Global Market Insights Inc. Patients with debilitating psychiatric and neurological disorders are benefiting from technological advancements in different types of neurostimulation devices. For example, in May 2019, Nevro launched Omnia, a next-generation spinal cord stimulation system, to treat chronic pain in the U.S. Apart from their increasing adoption for pain management, of neurostimulation devices are deemed effective for use in deep brain stimulation for movement control and other applications. Request...

Summary: After three quarters Gabriel Holding A/S delivers 39% revenue growth to DKK 812.7 million and operating profit (EBIT) of DKK 60.1 million, an increase of 40%.  Selected financial ratios:Revenue increased by DKK 226 million (39%) to DKK 812.7 million (DKK 586.4 million)Revenue in the third quarter increased by DKK 91.8 million to DKK 289.9 million (DKK 198.1 million), an increase of 46% All business units contributed to the realised growth in the first nine months of the yearThe gross margin was 32.9% (37.9%) Operating profit (EBIT) increased by 40% to DKK 60.1 million (DKK 43.0 million)Operating profit (EBIT) in the third quarter increased by 21% to DKK 16.1 million (DKK 13.3 million)Net finance income and costs in the period was positive by DKK 7.4 million, compared to an expense of DKK 5.5 million in the same period...